HR Execs on the Move

DICE Therapeutics

www.dicetherapeutics.com

 
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Scott Robertson
Chief Business and Financial Officer Profile

Similar Companies

Vanda Pharmaceuticals

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

iPierian

iPierian is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TissueTech

TissueTech, Inc is a Biotechnology company headquartered in Miami, FL. TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue, Inc: the industry leader in regenerative tissue therapies for ocular surface diseases and disorders. Amniox Medical: a leading technology provider to the musculoskeletal and wound care markets.

Tekmira Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.